The US FDA has approved Galderma's Nemluvio (nemolizumab), for individuals aged 12 years and above with moderate-to-severe atopic dermatitis.

Boehringer Ingelheim’s blockbuster Ofev could be set for an expanded indication in children and adolescents with fibrosing ILDs.

New HTA statistics produced by Denmark’s Medicinrådet for 2024 have prompted GlobalData to assess evolving HTA trends in the Nordic market.

The biopharmaceutical industry faces a future full of risks and rewards. But what role will 3PL suppliers play?

WuXi AppTec and WuXi Biologics are looking to sell off sites in the US and Europe as the prospect of the Biosecure Act is deterring potential clients.

Discover the latest advancements in small cell lung cancer through Novotech CRO’s in-depth disease analysis. Gain valuable insights into novel therapies, ongoing clinical trials, and future ...

AbbVie has entered into a definitive agreement to acquire Nimble Therapeutics in a deal valued at $200m in cash.